Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 1 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Neuroderm Ltd. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, providing a variety of reviews for the company's pharmaceutical innovations. All 4 actions are located within 1 distinct art unit, which centralizes the technical oversight of the portfolio. This concentration in 1 distinct art unit indicates that the company's 4 pending office actions are being evaluated within a single specialized division of the patent office. Practitioners can benefit from the procedural consistency provided by this 1 distinct art unit while addressing the individual styles of the 4 distinct examiners.
The busiest examiner, FAROOQ, MAHMOOD, is currently overseeing 1 pending office action. With 4 distinct examiners for the 4 total pending actions, the workload is evenly spread. This structure ensures that the 4 pending office actions receive independent evaluations from 4 different individuals within the same 1 distinct art unit. Practitioners should maintain a consistent technical narrative for the art unit while addressing the specific concerns of the 4 distinct examiners. The 4 pending office actions reflect a focused effort to secure intellectual property for the company's biotechnology innovations. This arrangement provides a stable regulatory context for the company's current pharmaceutical filings while allowing for multiple independent reviews of its claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAROOQ, MAHMOOD | 1 | 60.0% | +0.0% |
| SHIAO, REI TSANG | 1 | 79.8% | -33.6% |
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549452 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | CHO, DAVID H | 22d |
| 18632667 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS | HUI, SAN MING R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549452 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | CHO, DAVID H | 22d |
| 18632667 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843605 | MAGNETIC COUPLING AND DETECTION MECHANISM FOR A PUMP DEVICE | FAROOQ, MAHMOOD | — | §112 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18764647 | METHOD FOR TREATMENT OF PARKINSON'S DISEASE | SHIAO, REI TSANG | — | §103§112DP | Non-Final OA | — | Pending | Jul 05, 2024 |
| 18632667 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS | HUI, SAN MING R | — | §101DP | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18549452 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | CHO, DAVID H | 1693 | §102§103§112Other | Non-Final OA | 22d | Pending | Sep 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial